Prophylactic HIV Drugs Market Report Scope & Overview:

The Prophylactic HIV Drugs Market was valued at USD 33.52 Billion in 2025 and is expected to reach USD 50.00 Billion by 2035, growing at a CAGR of 4.08% from 2026-2035.

The Prophylactic HIV Drugs Market is witnessing increasing traction because of rising new infections, adoption of prophylactic drugs in the prevention programs at the national level, and transition from the pill form to long-acting injectable treatments. Twice-yearly or every second month regimen has reduced the adherence issues that earlier hindered the effectiveness of oral PrEP. Licensing has led to cost-effective generics in high-burden countries, and the tele-PrEP systems have simplified the process of prescriptions, tests, and medication refills for individuals unwilling to go to clinics. Predictable purchasing volumes for the drug makers catering to the high burden areas of the world have been generated by the funding commitment from the Global Fund and PEPFAR.

In July 2025, the World Health Organization issued guidelines recommending injectable lenacapavir as an additional HIV prevention option and endorsed rapid diagnostic testing to simplify PrEP initiation. The guidance gives national programs and donors a clear basis to procure twice-yearly prophylaxis, accelerating adoption in community and primary-care settings.

Prophylactic HIV Drugs Market Trends:

• Rising shift from daily oral PrEP to twice-yearly lenacapavir and bimonthly cabotegravir injectables.

• Growing voluntary licensing of long-acting agents to generic manufacturers for low-income countries.

• Expanding tele-PrEP and online pharmacy models offering remote testing and home delivery.

• Increasing development of once-monthly oral and ultra-long-acting prevention candidates.

• Growing donor-funded procurement of long-acting PrEP across sub-Saharan Africa.

• Rising integration of PrEP into sexual, reproductive, and primary healthcare services.

U.S. Prophylactic HIV Drugs Market Outlook:

The U.S. Prophylactic HIV Drugs Market was valued at USD 12.85 Billion in 2025 and is expected to reach USD 18.52 Billion by 2035, growing at a CAGR of 3.72% from 2026-2035.

The U.S. Prophylactic HIV Drugs Market is expanding owing to the Affordable Care Act requirement that most private plans cover PrEP and related testing without cost-sharing, which has removed a major financial barrier for users. The national Ending the HIV Epidemic initiative continues to channel federal funding toward high-incidence counties, particularly across the South. The country also leads in early launches of branded long-acting agents, giving prescribers access to injectables well before most other markets. Rapid growth of telehealth PrEP services and mail-order pharmacies is widening access in rural areas.

In June 2025, the U.S. FDA approved Gilead Sciences’ Yeztugo (lenacapavir), the first twice-yearly injectable for HIV pre-exposure prophylaxis in adults and adolescents weighing at least 35 kg. The approval, supported by the PURPOSE 1 and PURPOSE 2 trials, gives U.S. clinicians a prevention option that requires only two injections per year, reducing reliance on daily adherence.

Prophylactic HIV Drugs Market Segment Analysis:

• By Drug, the Tenofovir Alafenamide (TAF) segment dominated the Prophylactic HIV Drugs Market with approximately 53.62% share in 2025, while the Lenacapavir segment is the fastest growing with a CAGR of approximately 7.04%.

• By Dosage Form, the Oral Pill segment dominated the Prophylactic HIV Drugs Market with approximately 64.37% share in 2025, while the Long-Acting Injectable segment is the fastest growing with a CAGR of approximately 7.46%.

• By Prophylaxis Type, the Pre-Exposure Prophylaxis (PrEP) segment dominated the Prophylactic HIV Drugs Market with approximately 86.24% share in 2025 and is also the fastest growing with a CAGR of approximately 4.37%.

• By Distribution Channel, the Hospital Pharmacies segment dominated the Prophylactic HIV Drugs Market with approximately 54.73% share in 2025, while the Online Pharmacies & Tele-PrEP Platforms segment is the fastest growing with a CAGR of approximately 7.62%.

By Drug, TAF dominates, and Lenacapavir grows fastest

Tenofovir Alafenamide (TAF) held the leading position in the Prophylactic HIV Drugs Market in 2025, reflecting prescriber preference for its improved kidney and bone safety profile compared with older tenofovir formulations. In high-income markets, emtricitabine/TAF combinations such as Descovy are widely used for long-term prevention among men who have sex with men and transgender women. Branded pricing and broad insurance coverage in the United States add to the segment’s revenue weight. Clinicians often favor TAF-based regimens for older users and those with pre-existing renal risk, which keeps utilization stable even as generic TDF-based options become cheaper across both public and private channels.

Lenacapavir is the fastest-growing drug segment, as its capsid-inhibition mechanism offers a new class of prevention that sits outside reverse transcriptase and integrase pathways. The PURPOSE trials showed near-complete protection with only two injections per year, which directly addresses the adherence problems seen with daily pills. Regulatory approvals in the United States and Europe, followed by WHO prequalification, are opening both premium and donor-funded channels. Generic licensing across 120 low- and middle-income countries is expected to bring prices down sharply, supporting large-volume rollout through national programs and global health partners.

By Dosage Form, Oral Pill dominates, and Long-Acting Injectable grows fastest

Oral pill segment dominated the Prophylactic HIV Drugs Market in 2025 since TDF/FTC and TAF/FTC taken once daily in the form of pills continue to be the basis of guidelines, tenders, and formularies both nationally and internationally. In several developing countries, generics in tablet form may cost just a few dollars per month and become the primary choice for procurement programs of the government. Prescriptions and monitoring of these oral forms by pharmacists and doctors is easy, and event-driven dosing can also give users more convenience.

Long-acting injectables are growing fastest, as bimonthly cabotegravir and twice-yearly lenacapavir remove the burden of taking a pill every day. Users, especially young women and adolescents, often cite discretion and reduced stigma as key reasons for choosing injections. Health systems are building injection-ready clinics and pharmacy-based administration models to support scale-up. Donor funding from the Global Fund and PEPFAR is now being directed toward injectable procurement, while pipeline work on implants and ultra-long-acting formulations points to further diversification of delivery formats over the forecast period.

By Prophylaxis Type, PrEP dominates and grows fastest

Pre-exposure prophylaxis dominated the Prophylactic HIV Drugs Market in 2025, as prevention strategies have moved from reactive treatment after exposure toward continuous protection for people at ongoing risk. National AIDS programs in the United States, Europe, Brazil, South Africa, and Kenya now include PrEP as a core intervention, backed by public funding and insurance coverage. The recurring nature of PrEP, with monthly refills or scheduled injections, generates consistent revenue compared with short-course regimens. Growing awareness among key populations and expanded eligibility for women and adolescents continue to enlarge the treated base across both developed and emerging markets.

PrEP is also the fastest-growing prophylaxis type, supported by new long-acting products that improve persistence and by global targets to sharply increase the number of people on prevention. Post-exposure prophylaxis remains essential in emergency departments, occupational health, and sexual assault care, but its 28-day course limits overall revenue. Many programs now use PEP as an entry point, transitioning users to PrEP once the initial course ends. This PEP-to-PrEP pathway, combined with rapid testing and same-day starts, adds further volume to the pre-exposure segment.

By Distribution Channel, Hospital Pharmacies dominate, and Online & Tele-PrEP Platforms grow fastest

Hospital pharmacies dominated the Prophylactic HIV Drugs Market in 2025, owing to the baseline HIV testing, renal monitoring, and clinical follow-up required before and during prophylaxis. Specialist infectious disease and sexual health clinics attached to hospitals remain the main prescribers of new long-acting injectables, which require trained staff for administration. Hospitals also handle most post-exposure prophylaxis starts through emergency departments. Integrated care models, where testing, counseling, dispensing, and injections take place at a single site, reinforce the channel’s leading role, particularly in the United States and European public health systems.

Online pharmacies and PrEP apps have been growing quickly as people opt for telehealth visits, at-home testing, and discreet shipping options. This reduces travel time and stigma, which are important hurdles for rural and younger individuals. Reminders through apps for refills and lab work ensure that patients stick to their medication regimen. In the United States, insurance companies and public health authorities have formed partnerships with such organizations to provide healthcare services to disadvantaged populations, while the same trend is being followed in Europe and Asia-Pacific regions.

Regional Analysis:

North America Prophylactic HIV Drugs Market Insights

North America accounted for approximately 41.48% of the Prophylactic HIV Drugs Market in 2025, the largest share among all regions, supported by high branded drug prices, broad insurance coverage, and early access to new long-acting agents. The United States generates the vast majority of regional revenue, with private insurers and Medicaid required to cover PrEP without cost-sharing under the Affordable Care Act. Federal Ending the HIV Epidemic funding has expanded clinic capacity in high-incidence counties across the South. Gilead Sciences and ViiV Healthcare maintain strong commercial footprints, and a well-developed tele-PrEP ecosystem further supports prescription growth.

Canada continues to have a consistent presence, with several provinces, such as British Columbia, providing PrEP at no cost to their citizens. Evaluations carried out by Health Canada of long-lasting drugs and formulary listings will impact the adoption speed of injectable drugs. The Mexican market is relatively smaller but growing, because of expansion of access to PrEP services through dedicated clinics in Mexico City and other urban centers in the country.

Europe Prophylactic HIV Drugs Market Insights

Europe is the second-largest regional market, led by Germany, the UK, France, and Spain, where statutory health insurance or national health services fund PrEP for eligible users. Germany has reimbursed PrEP through statutory insurance since 2019, while England’s NHS provides it free through sexual health clinics. The European Commission’s authorization of lenacapavir, marketed as Yeytuo, in 2025 has added a twice-yearly option for prescribers. However, prevention coverage remains concentrated among men who have sex with men, leaving gaps among women and migrant communities.

France was an early adopter and continues to report among the highest PrEP user numbers in the region, supported by broad prescribing rights for general practitioners. Southern and Eastern European countries show lower uptake due to budget constraints, stigma, and uneven guideline implementation. Generic TDF/FTC tablets dominate tender-based procurement in most countries, keeping average prices low. Health technology assessments for long-acting injectables in markets such as Germany and France will determine how quickly premium formats gain share over the forecast period.

Asia-Pacific Prophylactic HIV Drugs Market Insights

Asia-Pacific is witnessing the highest growth rate in the Prophylactic HIV Drugs Market, anticipated to record a CAGR of around 5.42% during the forecast period from 2026 to 2035. Growth is driven by government-led PrEP expansion in Thailand, Vietnam, India, and the Philippines, where prevention is being built into universal health coverage programs. China is the largest market in the region, supported by rising awareness among key populations and approval of emtricitabine/tenofovir for prevention. Local generic manufacturing in India keeps oral regimens affordable, allowing wider rollout through public and NGO channels.

Australia has one of the most mature PrEP programs in the region, with subsidized access under the Pharmaceutical Benefits Scheme contributing to declining new infections in several states. Thailand’s community-led delivery model, supported by organizations such as the Thai Red Cross AIDS Research Centre, is often cited as a regional benchmark. Japan and South Korea have slower uptake due to limited reimbursement, but awareness is increasing. Smartphone-based tele-PrEP services in urban hubs are expected to accelerate adoption among younger users.

MEA & Latin America Prophylactic HIV Drugs Market Insights

The Middle East & Africa region carries the highest HIV burden worldwide, and sub-Saharan Africa accounts for the largest share of prevention volume, though revenue per user remains low due to generic pricing. South Africa leads the region with one of the world’s largest national PrEP programs, while Kenya, Zambia, Zimbabwe, and Eswatini are among the first countries introducing lenacapavir with donor support. Gulf Cooperation Council states contribute a smaller share, with access mainly through specialized hospital services.

Latin America is seeing steady growth in terms of access to PrEP through the SUS scheme of Brazil, which provides access to PrEP at zero cost at many dispensing locations. In addition to this, Mexico, Argentina, Colombia, and Peru have increased their prevention efforts through public funding and strong community health care network. However, there are many middle income countries in Latin America that fall outside the geographical boundaries for newer long acting products which increases prices.

Market Dynamics:

Growth Drivers: Persistent HIV Incidence and Long-Acting Innovation

Expansion in the Prophylactic HIV Drugs Market is still influenced by the prevalence of new cases. In 2024, the number of new cases estimated by UNAIDS was about 1.3 million cases. The adolescent girls and young women from sub-Saharan Africa together with key populations in Asia and Latin America are still under threat. It is getting common for governments and donors to consider the prevention strategy as a less costly way compared to lifelong therapy; therefore, more funds are provided for PrEP.

Innovation in long-acting drug delivery is another major growth driver. Twice-yearly lenacapavir and bimonthly cabotegravir have shown higher protection than daily pills in clinical trials, largely because they remove adherence issues. Late-stage candidates such as Merck’s once-monthly oral MK-8527 and ViiV’s ultra-long-acting cabotegravir formulations are expected to further broaden choice. These options allow clinicians to match regimens to user lifestyles, which improves persistence and supports steady prescription growth across both high-income and donor-funded markets.

Restraints: High Branded Prices and Access Disparities

High prices of branded long-acting agents limit adoption in many markets. In the United States, the annual list price of lenacapavir for PrEP is well above USD 25,000, leading some insurers to apply prior authorization and step-therapy rules. Middle-income countries outside generic licensing territories face the biggest affordability challenges, as they cannot access low-cost versions yet lack the budgets for branded products. These pricing gaps slow the transition from daily oral pills to newer injectable options.

Structural barriers also restrain growth. Stigma around HIV and sexual behavior continues to deter many people from seeking PrEP, especially in conservative societies. Rural clinics often lack trained staff, testing capacity, and reliable supply chains needed for injectable programs. Cuts or delays in international donor funding can disrupt procurement cycles and program continuity. Limited internet connectivity in low-resource settings also reduces the reach of tele-PrEP models, leaving large portions of at-risk populations underserved.

Opportunities: Generic Licensing and Digital Delivery Expansion

Licensing of lenacapavir and cabotegravir voluntarily to generic companies would provide a valuable way to make sure that millions of additional users are reached in countries most affected by the disease. The support from partnerships with the Global Fund, Unitaid, and the Bill & Melinda Gates Foundation will allow reaching the goal of achieving USD 40 per patient annually, which will facilitate implementation. Companies with capabilities of manufacturing high-quality, affordable medicines will be able to win tenders from governments and donors, while originators will receive royalties and greater impact on public health.

The use of digital health technologies and alternative delivery channels provides another opportunity for growth. Tele-PrEP services, prescribing through pharmacists, and home-testing kits reduce the challenges of travel, stigma, and capacity in clinics. Combining PrEP with reproductive health services, prenatal care, and general practice increases access to the product for women, who are unlikely to attend sexual health clinics. Pipeline products such as implants, vaginal rings, and broadly neutralizing antibodies are some of the opportunities.

Recent Developments:

• 2025, Gilead Sciences received European Commission marketing authorization for Yeytuo (lenacapavir), a twice-yearly injectable for HIV pre-exposure prophylaxis, making it available to prescribers across the European Union.

• 2025, Gilead Sciences and the Global Fund signed an agreement to supply lenacapavir for PrEP to up to two million people over three years in low- and middle-income countries, at no profit to Gilead.

• 2025, Dr. Reddy’s Laboratories partnered with Unitaid and other global health organizations to make generic lenacapavir for PrEP available at around USD 40 per person per year in 120 countries.

• 2025, Merck & Co. initiated the Phase 3 EXPrESSIVE-10 and EXPrESSIVE-11 trials evaluating MK-8527, an investigational once-monthly oral pill for HIV pre-exposure prophylaxis, across multiple countries.

• 2024, Emcure Pharmaceuticals secured a royalty-free voluntary license from Gilead Sciences to manufacture and supply generic lenacapavir across 120 high-incidence, resource-limited countries.

Prophylactic HIV Drugs Market Key Players:

• Gilead Sciences, Inc.

• ViiV Healthcare (GSK plc)

• Merck & Co., Inc.

• Johnson & Johnson (Janssen Pharmaceuticals)

• AbbVie Inc.

• Bristol-Myers Squibb Company

• Pfizer Inc.

• F. Hoffmann-La Roche AG

• Boehringer Ingelheim International GmbH

• Cipla Ltd.

• Viatris Inc.

• Teva Pharmaceutical Industries Ltd.

• Sun Pharmaceutical Industries Ltd.

• Aurobindo Pharma Ltd.

• Hetero Labs Ltd.

• Lupin Limited

• Macleods Pharmaceuticals Ltd.

• Emcure Pharmaceuticals Ltd.

• Dr. Reddy’s Laboratories Ltd.

• Apotex Inc.

Prophylactic HIV Drugs Market Report Scope: